For example, a clinical trial for Alzheimer’s disease where nerve-growth factor (NGF) was delivered via adeno-associated viral vectors (AAV2–NGF) failed due to the limited spread of AAV2-NGF to target cholinergic neurons [158]. This evidence concerns the gene NGF and early-onset autosomal dominant Alzheimer disease.